Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.80 -2.7%	$1.88	$1.21 ▼ $3.81	$44.46M	0.68	258,761 shs	76,079 shs
ATNM Actinium Pharmaceuticals	$1.71 +5.6%	$1.58	$1.03 ▼ $8.64	$53.35M	-0.32	525,057 shs	241,883 shs
EGRX Eagle Pharmaceuticals	$3.70 +0.3%	$2.53	$1.50 ▼ $3.87	$23.38M	0.83	7,688 shs	1,368 shs
NVLN Novelion Therapeutics		$0.70	$0.54 ▼ $2.35	$13.77M	2.12	190,529 shs	26,947 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	-2.70%	-5.76%	-12.20%	+14.65%	+14.65%
ATNM Actinium Pharmaceuticals	0.00%	+12.50%	+17.12%	+41.32%	-76.89%
EGRX Eagle Pharmaceuticals	0.00%	+4.23%	+57.45%	+105.56%	-38.13%
NVLN Novelion Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.4652 of 5 stars	1.0	0.0	0.0	0.0	0.0	2.5	1.3
ATNM Actinium Pharmaceuticals	2.1887 of 5 stars	3.4	5.0	0.0	0.0	0.6	0.0	0.6
EGRX Eagle Pharmaceuticals	2.559 of 5 stars	0.0	3.0	0.0	3.9	0.6	3.3	0.0
NVLN Novelion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.67	-7.41% Downside
ATNM Actinium Pharmaceuticals	2.75	Moderate Buy	$4.00	133.92% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
NVLN Novelion Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVLN, ATNM, EGRX, and AADI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/28/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.77	N/A	N/A	$4.29 per share	0.42
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
EGRX Eagle Pharmaceuticals	$257.55M	0.19	$9.25 per share	0.40	N/A	∞
NVLN Novelion Therapeutics	$130.43M	0.00	N/A	N/A	($4.69) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	8/5/2025 (Estimated)
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.47	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NVLN Novelion Therapeutics	-$108.33M	N/A	0.00	N/A	N/A	-79.43%	N/A	-26.13%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVLN Novelion Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
NVLN Novelion Therapeutics	N/A	0.24	0.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
ATNM Actinium Pharmaceuticals	27.50%
EGRX Eagle Pharmaceuticals	85.36%
NVLN Novelion Therapeutics	35.00%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
ATNM Actinium Pharmaceuticals	6.00%
EGRX Eagle Pharmaceuticals	28.90%
NVLN Novelion Therapeutics	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
NVLN Novelion Therapeutics	109	19.62 million	N/A	Optionable

NVLN, ATNM, EGRX, and AADI Headlines

Recent News About These Companies

CYTO - Altamira Therapeutics Ltd.

June 2, 2023 | finance.yahoo.com

Boston startup Ascidian Therapeutics charts vision for therapies that ‘rewrite RNA’

October 14, 2022 | bostonglobe.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVLN, ATNM, EGRX, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.80 -0.05 (-2.70%)

As of 07/18/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Actinium Pharmaceuticals NYSE:ATNM

$1.71 +0.09 (+5.56%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.01 (+0.29%)

As of 07/18/2025 07:16 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.70 +0.01 (+0.27%)

As of 07/18/2025 11:04 AM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Novelion Therapeutics NASDAQ:NVLN

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time